Last update 13 Jul 2024

Trastuzumab-PKRB(Celltrion)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
trastuzumab, Trastuzumab biosimilar, Trastuzumab biosimilar (Celltrion)
+ [3]
Target
Mechanism
HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
EU
09 Feb 2018
Breast Cancer
IS
09 Feb 2018
Breast Cancer
LI
09 Feb 2018
Breast Cancer
NO
09 Feb 2018
HER2 Positive Breast Cancer
EU
09 Feb 2018
HER2 Positive Breast Cancer
IS
09 Feb 2018
HER2 Positive Breast Cancer
LI
09 Feb 2018
HER2 Positive Breast Cancer
NO
09 Feb 2018
HER2-positive gastric cancer
EU
09 Feb 2018
HER2-positive gastric cancer
IS
09 Feb 2018
HER2-positive gastric cancer
LI
09 Feb 2018
HER2-positive gastric cancer
NO
09 Feb 2018
Hormone receptor positive breast cancer
EU
09 Feb 2018
Hormone receptor positive breast cancer
IS
09 Feb 2018
Hormone receptor positive breast cancer
LI
09 Feb 2018
Hormone receptor positive breast cancer
NO
09 Feb 2018
Metastatic Gastric Carcinoma
EU
09 Feb 2018
Metastatic Gastric Carcinoma
IS
09 Feb 2018
Metastatic Gastric Carcinoma
LI
09 Feb 2018
Metastatic Gastric Carcinoma
NO
09 Feb 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Gastroesophageal Junction AdenocarcinomaPhase 2
KR
10 Jun 2018
Neoplasm MetastasisPhase 2
KR
10 Jun 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
642
ftgtaunion(elnrcxtdqu) = ikbhphxfma vzueomadoz (qvofzkljta )
Positive
31 May 2023
Phase 2
128
treatment of physician's choice +Herzuma
vpzmlskcgt(qftfpigsjw) = fspnuwvopo wuztkesnfr (ohttikmvpj, 2.8 - 7.2)
Positive
17 Aug 2022
Phase 2
43
olkqnsugaj(qolblynrxp) = gohxvaxufu chweoxhmmh (gkgdhlndzi, 52 - 81)
Met
Positive
02 Jun 2022
Phase 3
HER2 Positive Breast Cancer
Neoadjuvant
HER2-positive
549
auhjpkzlgo(wdzsgzrexp) = mzflmosiff sttyzfmhts (njetspgnoe, 40.4 ~ 53.2)
Similar
01 Jul 2017
auhjpkzlgo(wdzsgzrexp) = ponqvkvitp sttyzfmhts (njetspgnoe, 44.1 ~ 56.7)
Phase 3
475
jsmustrque(vuatmaxetw) = qjllxeytwt olavnfliso (vwlcyipsau )
-
20 May 2013
jsmustrque(vuatmaxetw) = orblulvaqn olavnfliso (vwlcyipsau )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free